GV's David Schenkein comes in to help mentor — and bankroll — a gene therapy 2.0 player, intrigued by their ‘science heavy’ approach to conquering severe disease

A year ago, Encoded Therapeutics burst on the scene with a $104 million mega-raise that spotlighted their work on gene therapy 2.0 — focused on …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GV's David Schenkein comes in to help men­tor — and bankroll — a gene ther­a­py 2.0 play­er, in­trigued by their ‘sci­ence heavy’ ap­proach to con­quer­ing se­vere dis­ease